Summary of findings 2. Standard‐dose adjuvant radiotherapy alone versus adjuvant chemoradiotherapy.

Standard‐dose adjuvant radiotherapy alone compared with adjuvant chemoradiotherapy for patients with HPV‐positive oropharyngeal carcinoma who have received minimally invasive transoral surgery
Patient or population: patients with HPV‐positive oropharyngeal carcinoma who have received minimally invasive transoral surgery Settings: post minimally invasive transoral surgery Intervention: standard‐dose adjuvant radiotherapy alone Comparison: adjuvant chemoradiotherapy
Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk
	Adjuvant chemoradiotherapy	Standard‐dose adjuvant radiotherapy alone
Overall survival Follow‐up: at 1, 2, 3 and 5 years	No data available (no included studies)
Disease‐free survival Follow‐up: at 1, 2, 3 and 5 years	No data available (no included studies)
Swallowing ability Follow‐up: at 1, 6, 12 and 24 months	No data available (no included studies)
Voice (Voice Handicap Index) Follow‐up: at 1, 6, 12 and 24 months	No data available (no included studies)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate.